Wang Q, Wang J, Mathur R, Youngblood M, Jin Q, Hou Y
Sci Adv. 2025; 11(11):eadn2830.
PMID: 40073147
PMC: 11900876.
DOI: 10.1126/sciadv.adn2830.
Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A
Mol Cancer. 2025; 24(1):58.
PMID: 40011944
PMC: 11863469.
DOI: 10.1186/s12943-025-02267-0.
Jin Y, Zhang B, Li J, Guo Z, Zhang C, Chen X
Sci Adv. 2025; 11(8):eadr9266.
PMID: 39970222
PMC: 11838010.
DOI: 10.1126/sciadv.adr9266.
Manzanares-Guzman A, Alfonseca-Ladron de Guevara A, Reza-Escobar E, Burciaga-Flores M, Canales-Aguirre A, Esquivel-Solis H
Int J Mol Sci. 2025; 26(3).
PMID: 39940647
PMC: 11817625.
DOI: 10.3390/ijms26030876.
Wood J, Smith S, Castellanos-Uribe M, Lourdusamy A, May S, Barrett D
Heliyon. 2025; 11(1):e41309.
PMID: 39816516
PMC: 11732679.
DOI: 10.1016/j.heliyon.2024.e41309.
The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?.
Spallotta F, Illi B
Biomedicines. 2024; 12(11).
PMID: 39595195
PMC: 11591585.
DOI: 10.3390/biomedicines12112631.
Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.
Zhang Z, Geng X, Yin M, Zhang S, Liu Y, Hu D
World J Surg Oncol. 2024; 22(1):273.
PMID: 39390580
PMC: 11468453.
DOI: 10.1186/s12957-024-03558-4.
Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?.
Alnahhas I
Curr Oncol Rep. 2024; 26(11):1277-1282.
PMID: 39361075
PMC: 11579106.
DOI: 10.1007/s11912-024-01602-w.
Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis.
Karami Fath M, Nazari A, Parsania N, Behboodi P, Ketabi S, Razmjouei P
Med Oncol. 2024; 41(11):254.
PMID: 39352464
DOI: 10.1007/s12032-024-02524-0.
Biomarkers in Cerebrospinal Fluid for the Diagnosis and Monitoring of Gliomas.
Papadimitrakis D, Perdikakis M, Gargalionis A, Papavassiliou A
Biomolecules. 2024; 14(7).
PMID: 39062515
PMC: 11274947.
DOI: 10.3390/biom14070801.
Targeting drug resistance in glioblastoma (Review).
Sherman J, Bobak A, Arsiwala T, Lockman P, Aulakh S
Int J Oncol. 2024; 65(2).
PMID: 38994761
PMC: 11251740.
DOI: 10.3892/ijo.2024.5668.
Current status of precision oncology in adult glioblastoma.
Weller J, Potthoff A, Zeyen T, Schaub C, Duffy C, Schneider M
Mol Oncol. 2024; 18(12):2927-2950.
PMID: 38899374
PMC: 11619805.
DOI: 10.1002/1878-0261.13678.
Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.
Sadowski K, Jazdzewska A, Kozlowski J, Zacny A, Lorenc T, Olejarz W
Int J Mol Sci. 2024; 25(11).
PMID: 38891962
PMC: 11172387.
DOI: 10.3390/ijms25115774.
Targeting FGFR for cancer therapy.
Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T
J Hematol Oncol. 2024; 17(1):39.
PMID: 38831455
PMC: 11149307.
DOI: 10.1186/s13045-024-01558-1.
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Picca A, Di Stefano A, Savatovsky J, Ducray F, Chinot O, Moyal E
Neurooncol Adv. 2024; 6(1):vdae068.
PMID: 38813112
PMC: 11135358.
DOI: 10.1093/noajnl/vdae068.
Spatial analysis of recurrent glioblastoma reveals perivascular niche organization.
Onubogu U, Gatenbee C, Prabhakaran S, Wolfe K, Oakes B, Salatino R
JCI Insight. 2024; 9(12).
PMID: 38805346
PMC: 11383164.
DOI: 10.1172/jci.insight.179853.
The Invasion Factor ODZ1 Is Upregulated through an Epidermal Growth Factor Receptor-Induced Pathway in Primary Glioblastoma Cells.
Velasquez C, Gutierrez O, Carcelen M, Fernandez-Luna J
Cells. 2024; 13(9.
PMID: 38727302
PMC: 11083495.
DOI: 10.3390/cells13090766.
Tracking single-cell evolution using clock-like chromatin accessibility loci.
Xiao Y, Jin W, Ju L, Fu J, Wang G, Yu M
Nat Biotechnol. 2024; .
PMID: 38724668
DOI: 10.1038/s41587-024-02241-z.
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.
Crepaldi T, Gallo S, Comoglio P
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675409
PMC: 11054789.
DOI: 10.3390/ph17040448.
3C methods in cancer research: recent advances and future prospects.
Yoon I, Kim U, Jung K, Song Y, Park T, Lee D
Exp Mol Med. 2024; 56(4):788-798.
PMID: 38658701
PMC: 11059347.
DOI: 10.1038/s12276-024-01236-9.